The tweet was deleted by the author.
But we saved everything 🙂.
Allogene Therapeutics has announced that the U.S. Food and Drug Administration has granted both RMAT and Fast Track designations to its investigational, off-the-shelf allogeneic CAR-T product, cema-cel, for the treatment of large B-cell lymphoma (LBCL).
These FDA designations aim to expedite the development and review process for therapies targeting serious or life-threatening conditions, underscoring the momentum behind Allogene Therapeutics’ cell therapy pipeline. The company positions this regulatory milestone as a significant step in bringing a novel off-the-shelf CAR-T therapy to patients with LBCL. Further details about the program and next development steps are available on the company’s official website.
View post on X Loading...
Allogene Therapeutics recently launched the ALPHA3 trial to evaluate a new consolidation approach aiming to reduce relapse in patients with large B-cell lymphoma. The company is also advancing clinical work that integrates MRD testing with its off-the-shelf CAR-T platform to support early intervention efforts in LBCL. These initiatives reflect Allogene’s continued focus on improving treatment outcomes in the LBCL setting.